Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Subscribe To Our Newsletter & Stay Updated
